{
    "popularityCurve": {
        "data": [
            1,
            1,
            1
        ],
        "xLabels": [
            "02:14",
            "03:08",
            "04:28"
        ],
        "label": {
            "phrase": "we are very pleased with the terms and response from investors that resulted in an over-subscribed offering the investors that participated are leading institutional funds and accredited investors the fact that we have been able to close this transaction on what we consider to be favorable terms we believe speaks to the potential of our drug pipeline and the importance of the illnesses and diseases we are combating this financing gives polymedix the capital to advance our two lead drug development programs into human clinical development and the important phase ib proof of concept studies this is an important milestone in our growth and we are enthusiastically pressing forward with drug development programs that we believe offer innovative life-saving therapies for serious infectious and cardiovascular diseases",
            "count": 1
        }
    },
    "clusterList": [
        {
            "phrase": "we are very pleased with the terms and response from investors that resulted in an over-subscribed offering the investors that participated are leading institutional funds and accredited investors the fact that we have been able to close this transaction on what we consider to be favorable terms we believe speaks to the potential of our drug pipeline and the importance of the illnesses and diseases we are combating this financing gives polymedix the capital to advance our two lead drug development programs into human clinical development and the important phase ib proof of concept studies this is an important milestone in our growth and we are enthusiastically pressing forward with drug development programs that we believe offer innovative life-saving therapies for serious infectious and cardiovascular diseases",
            "count": 1
        },
        {
            "phrase": "for bristol-myers squibb the proposed acquisition of imclone represents a strategically and financially sound add-on to our business consolidating a relationship we have had for nearly seven years",
            "count": 1
        },
        {
            "phrase": "corporations are donating millions abbot lab-2 million",
            "count": 1
        }
    ]
}